The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 13.41 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as Protagonist Therapeutics, Inc reports it. History and quarterly detail are in the app.
- Development Services$24.7M
Leadership changes
From Protagonist Therapeutics, Inc's own filings, the day they're filed.
- Sarah A. O'Dowd · Directors · appointmenteff. 2024-09-19
- Daniel N. Swisher Jr · member · departureeff. 2024-09-17
- Daniel N. Swisher Jr · appointment
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-18
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Protagonist Therapeutics, Inc, every answer cited to the official filings🔒
- The Intelligence Brief — added when Protagonist Therapeutics, Inc's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.